Mustafa Noor, MD, FACP

Mustafa Noor, MD, FACP brings in 18+ years of experience in all phases of clinical development focused on cardiometabolic, endocrine and rare disease in both large and small companies.

Most recently Dr. Noor was Chief Development Officer at Akcea Therapeutics in Cambridge, MA and responsible for the integrated activities of clinical development overseeing a portfolio of antisense oligonucleotides for rare cardiometabolic diseases.  Earlier he was VP and TA head for endocrinology at IPSEN where he oversaw successful submission of rare disease sNDA for lanreotide in neuroendocrine tumors and MAA filing for telotristat (Xermelo) for the rare disease of carcinoid syndrome in the EU as part of a strategic collaboration between IPSEN and Lexicon Pharmaceuticals.

Dr. Noor began his career as medical director with BMS in 2001 where he contributed to clinical development of metabolic, cardiovascular and HIV antiviral programs in positions of increasing responsibility leading market differentiation of Reyataz as a lipid and metabolic friendly HIV therapeutic. From 2006 to 2014 he was at GSK and at Pfizer where he served as vice president and clinical head for GSK’s Center of Excellence in External Drug Discovery (CEEDD) and for Pfizer’s Centers for Therapeutic Innovation (CTI) focusing on open innovation, translational research and collaboration with biotech and academic partners on a portfolio of multiple programs in early phase trials.

Dr. Noor completed his undergraduate and medical degrees at the University of Chicago and fellowship training in Endocrinology and Metabolism at the University of California, San Francisco (UCSF). He is certified in internal medicine and the subspecialty of endocrinology & metabolism and holds a Master’s Degree in clinical research from Vanderbilt University School of Medicine.